US5171563A
(en)
*
|
1988-09-30 |
1992-12-15 |
Neorx Corporation |
Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
|
WO1991007991A1
(en)
*
|
1989-11-30 |
1991-06-13 |
Mallinckrodt Medical, Inc. |
Method for preparing a metal-radionuclide-labelled protein
|
WO1992001474A1
(en)
*
|
1990-07-20 |
1992-02-06 |
Kabi Pharmacia Ab |
Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
|
DE4430023A1
(de)
*
|
1994-08-24 |
1996-02-29 |
Boehringer Mannheim Gmbh |
Elektrochemischer Sensor
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6133436A
(en)
*
|
1996-11-06 |
2000-10-17 |
Sequenom, Inc. |
Beads bound to a solid support and to nucleic acids
|
ATE259056T1
(de)
*
|
1996-11-06 |
2004-02-15 |
Sequenom Inc |
Verfahren zur massenspektrometrie
|
US7285422B1
(en)
|
1997-01-23 |
2007-10-23 |
Sequenom, Inc. |
Systems and methods for preparing and analyzing low volume analyte array elements
|
AU9318498A
(en)
*
|
1997-09-18 |
1999-04-05 |
Pierce Chemical Company |
Sulfo-n-hydroxy succinimide and method of preparation
|
US5892057A
(en)
|
1997-09-18 |
1999-04-06 |
Pierce Chemical Company |
Preparation of sulfo-N-hydroxysuccinimide salts
|
EP1982990A1
(de)
|
1998-03-19 |
2008-10-22 |
Human Genome Sciences, Inc. |
Zytokinrezeptor wie eine gemeinsame Gammakette
|
US7094943B2
(en)
|
1998-04-27 |
2006-08-22 |
Hubert Köster |
Solution phase biopolymer synthesis
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
AU765588C
(en)
|
1999-11-24 |
2004-12-16 |
Immunogen, Inc. |
Cytotoxic agents comprising taxanes and their therapeutic use
|
AU2002219944B2
(en)
|
2000-11-28 |
2008-02-21 |
Medimmune, Llc |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
WO2001096528A2
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
PT2275449T
(pt)
|
2000-06-16 |
2016-12-27 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente a blys
|
US20020142483A1
(en)
|
2000-10-30 |
2002-10-03 |
Sequenom, Inc. |
Method and apparatus for delivery of submicroliter volumes onto a substrate
|
JP2005503116A
(ja)
|
2001-02-09 |
2005-02-03 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトgタンパク質ケモカインレセプター(ccr5)hdgnr10
|
DE60236646D1
(de)
|
2001-04-13 |
2010-07-22 |
Human Genome Sciences Inc |
Anti-VEGF-2 Antikörper
|
WO2002097033A2
(en)
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
JP2005535572A
(ja)
|
2002-04-12 |
2005-11-24 |
メディミューン,インコーポレーテッド |
組換え抗インターロイキン−9抗体
|
BR0313197A
(pt)
|
2002-08-02 |
2005-08-09 |
Immunogen Inc |
Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス, インコーポレイテッド |
抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
PT2248899E
(pt)
|
2003-03-19 |
2015-09-23 |
Biogen Ma Inc |
Proteína de ligação do receptor nogo
|
EP1628992A4
(de)
|
2003-05-13 |
2008-04-16 |
Novartis Vaccines & Diagnostic |
Verfahren zur modulation der metastasierung sowie von metastasen herrührender verwandter ereignisse im skelett
|
JP4943161B2
(ja)
|
2003-12-23 |
2012-05-30 |
ジェネンテック, インコーポレイテッド |
新規抗il13モノクローナル抗体での癌の処置
|
ES2395094T3
(es)
|
2004-06-24 |
2013-02-08 |
Biogen Idec Ma Inc. |
Tratamiento de afecciones que implican la desmielinización
|
BRPI0512928A
(pt)
*
|
2004-06-30 |
2008-04-15 |
Novartis Ag |
composições e métodos para liberação de agentes de antitumor
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
WO2006078776A2
(en)
|
2005-01-19 |
2006-07-27 |
The Trustees Of The University Of Pennsylvania |
Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
MX2008000253A
(es)
|
2005-07-08 |
2008-04-02 |
Biogen Idec Inc |
Anticuerpos de sp35 y usos de los mismos.
|
US7482124B2
(en)
|
2005-07-08 |
2009-01-27 |
Bristol-Myers Squibb Company |
Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
|
MX2008005764A
(es)
|
2005-11-04 |
2008-11-18 |
Biogen Idec Inc |
Metodos para promover el crecimiento de neuritas y la supervivencia en neuronas dopaminergicas.
|
PL2500030T5
(pl)
|
2005-11-04 |
2019-02-28 |
Genentech, Inc. |
Zastosowanie inhibitorów drogi aktywacji dopełniacza w leczeniu chorób oczu
|
JP5191392B2
(ja)
|
2005-11-07 |
2013-05-08 |
ザ スクリプス リサーチ インスティチュート |
組織因子シグナル伝達の特異性を調節するための組成物及び方法
|
JP5312039B2
(ja)
|
2005-12-02 |
2013-10-09 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
脱髄の関与する状態の処置
|
CN103215293B
(zh)
|
2006-01-27 |
2015-10-28 |
比奥根Ma公司 |
Nogo受体拮抗剂
|
JP2009541208A
(ja)
|
2006-04-13 |
2009-11-26 |
ノバルティス・バクシーンズ・アンド・ダイアグノスティクス・インコーポレイテッド |
がんを処置し、診断しもしくは検出する方法
|
CA2652703C
(en)
|
2006-06-07 |
2018-08-28 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
EP2064243A2
(de)
|
2006-08-28 |
2009-06-03 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistische lichtspezifische menschliche monoklonale antikörper
|
US9382327B2
(en)
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
US8455622B2
(en)
|
2006-12-01 |
2013-06-04 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
US7935791B2
(en)
|
2006-12-18 |
2011-05-03 |
Genentech, Inc. |
Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
|
CN103408661B
(zh)
|
2007-01-05 |
2016-04-06 |
苏黎世大学 |
提供疾患特异性结合分子和靶的方法
|
DK2740744T3
(da)
|
2007-01-09 |
2018-04-23 |
Biogen Ma Inc |
Sp35-antistoffer og anvendelser deraf
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
GEP20135853B
(en)
|
2007-02-02 |
2013-06-25 |
Univ Pierre And Marie Curie |
Method of myelination and oligodendrocyte differentiation promotion
|
JP2010521180A
(ja)
|
2007-03-14 |
2010-06-24 |
ノバルティス アーゲー |
癌を処置、診断または検出するためのapcdd1阻害剤
|
TW200902547A
(en)
|
2007-04-27 |
2009-01-16 |
Genentech Inc |
Potent, stable and non-immunosuppressive anti-CD4 antibodies
|
CA2698203C
(en)
|
2007-08-29 |
2018-09-11 |
Sanofi-Aventis |
Humanized anti-cxcr5 antibodies, derivatives thereof and their use
|
WO2009039122A2
(en)
|
2007-09-17 |
2009-03-26 |
Sequenom, Inc. |
Integrated robotic sample transfer device
|
WO2009046407A2
(en)
|
2007-10-04 |
2009-04-09 |
Zymogenetics, Inc. |
B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
US8236316B2
(en)
|
2007-11-21 |
2012-08-07 |
Oregon Health & Science University |
Anti-factor XI monoclonal antibodies and methods of use thereof
|
AU2008338313B2
(en)
|
2007-12-18 |
2014-01-16 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
|
CA2710680C
(en)
|
2007-12-26 |
2018-10-16 |
Vaccinex, Inc. |
Anti-c35 antibody combination therapies and methods
|
EP2260102A1
(de)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
|
EP2288715B1
(de)
|
2008-04-11 |
2014-09-24 |
Merrimack Pharmaceuticals, Inc. |
Humanserumalbumin-linker und konjugate davon
|
NZ588408A
(en)
|
2008-04-16 |
2012-05-25 |
Biogen Idec Inc |
Method of isolating proteins using polyethylene glycol and zinc
|
DK2982695T3
(da)
|
2008-07-09 |
2019-05-13 |
Biogen Ma Inc |
Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
|
CA2735433C
(en)
|
2008-09-07 |
2016-02-16 |
Glyconex Inc. |
Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
|
SI2949666T1
(sl)
|
2008-12-19 |
2019-03-29 |
Biogen International Neuroscience Gmbh |
Človeška anti alfa-sinukleinska protitelesa
|
US20120003235A1
(en)
|
2008-12-31 |
2012-01-05 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
WO2010100247A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
EP2411412B1
(de)
|
2009-03-24 |
2015-05-27 |
Teva Biopharmaceuticals USA, Inc. |
Humanisierte antikörper gegen licht und anwendungen davon
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
CN108912228B
(zh)
|
2009-05-08 |
2022-03-15 |
瓦西尼斯公司 |
抗-cd100抗体和其使用方法
|
US8568719B2
(en)
|
2009-08-13 |
2013-10-29 |
Crucell Holland B.V. |
Antibodies against human respiratory syncytial virus (RSV) and methods of use
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
EP2480573A1
(de)
|
2009-09-22 |
2012-08-01 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krebs durch modulation von mex-3
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
AU2010315101B2
(en)
|
2009-11-04 |
2016-01-28 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
MX2012006443A
(es)
|
2009-12-09 |
2012-06-28 |
Inst Nat Sante Rech Med |
Anticuerpos monoclonales que se enlazan a b7h6 y usos de los mismos.
|
EP2542578A1
(de)
|
2010-03-05 |
2013-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Smoc1, tenascin-c und hirnkrebs
|
WO2011131611A1
(en)
|
2010-04-19 |
2011-10-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
US20130089538A1
(en)
|
2010-06-10 |
2013-04-11 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
EA027835B1
(ru)
|
2010-07-09 |
2017-09-29 |
Круселл Холланд Б.В. |
Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
|
WO2012025636A1
(en)
|
2010-08-27 |
2012-03-01 |
University Of Zurich |
Method for target and drug validation in inflammatory and/or cardiovascular diseases
|
NZ608318A
(en)
|
2010-09-02 |
2015-03-27 |
Vaccinex Inc |
Anti-cxcl13 antibodies and methods of using the same
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
JP2014503178A
(ja)
|
2010-10-11 |
2014-02-13 |
バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー |
ヒト抗タウ抗体
|
WO2012065937A1
(en)
|
2010-11-15 |
2012-05-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
SG190938A1
(en)
|
2010-12-06 |
2013-07-31 |
Seattle Genetics Inc |
Humanized antibodies to liv-1 and use of same to treat cancer
|
US9283271B2
(en)
|
2010-12-17 |
2016-03-15 |
Neurimmune Holding Ag |
Human anti-SOD1 antibodies
|
EP3235508B1
(de)
|
2011-03-16 |
2020-12-30 |
Sanofi |
Zubereitungen enthaltend ein antikörperähnliches protein mit dualer v-region
|
US9127065B2
(en)
|
2011-05-19 |
2015-09-08 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anti-human HER3 antibodies and uses thereof
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
EP2723376B1
(de)
|
2011-06-22 |
2018-12-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-axl-antikörper und verwendungen damit
|
CN103747803B
(zh)
|
2011-06-22 |
2016-10-12 |
国家医疗保健研究所 |
抗axl抗体及其用途
|
CA2839563C
(en)
|
2011-06-23 |
2019-10-29 |
Biogen Idec International Neuroscience Gmbh |
Anti-alpha synuclein binding molecules
|
US20140234903A1
(en)
|
2011-09-05 |
2014-08-21 |
Eth Zurich |
Biosynthetic gene cluster for the production of peptide/protein analogues
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
JP2014533247A
(ja)
|
2011-11-01 |
2014-12-11 |
バイオノミクス インコーポレイテッド |
抗体および癌を治療する方法
|
ES2697674T3
(es)
|
2011-11-01 |
2019-01-25 |
Bionomics Inc |
Procedimientos para bloquear el crecimiento de células madre cancerosas
|
EP2773667A1
(de)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49-antikörper
|
EP2776838A1
(de)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Frühe diagnose neurodegenerativer erkrankungen
|
EP2776022A1
(de)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Neue behandlung für neurodegenerative erkrankungen
|
TWI640537B
(zh)
|
2011-12-05 |
2018-11-11 |
X 染色體有限公司 |
PDGF受體β結合多肽
|
EP2800583A1
(de)
|
2012-01-02 |
2014-11-12 |
Novartis AG |
Cdcp1 und brustkrebs
|
CA2865928C
(en)
|
2012-03-02 |
2021-02-16 |
Vaccinex, Inc. |
Cxcl13 antagonist for the treatment of sjogren's syndrome
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
TWI605060B
(zh)
|
2012-03-28 |
2017-11-11 |
賽諾菲公司 |
抗緩激肽b1受體配位體之抗體
|
WO2013144240A1
(en)
|
2012-03-29 |
2013-10-03 |
Friedrich Miescher Institute For Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
CA2872856A1
(en)
|
2012-05-07 |
2013-11-14 |
Sanofi |
Methods for preventing biofilm formation
|
WO2013173364A2
(en)
|
2012-05-14 |
2013-11-21 |
Biogen Idec Ma Inc. |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
CN104603149B
(zh)
|
2012-05-24 |
2017-06-30 |
万机集团有限公司 |
与预防和治疗狂犬病感染相关的组合物和方法
|
WO2014001482A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
EP2870242A1
(de)
|
2012-07-05 |
2015-05-13 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Neue behandlung für neurodegenerative erkrankungen
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
CN104662044B
(zh)
|
2012-08-24 |
2018-10-30 |
加利福尼亚大学董事会 |
用于治疗ror1癌症并抑制转移的抗体和疫苗
|
US10189906B2
(en)
|
2012-11-01 |
2019-01-29 |
Max-Delrück-Centrum Für Molekulare Medizin |
Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
EA035932B1
(ru)
|
2012-12-21 |
2020-09-02 |
Байоджен Ма Инк. |
Человеческие анти-тау антитела
|
US9771413B2
(en)
|
2012-12-31 |
2017-09-26 |
Neurimmune Holding Ag |
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
|
WO2014137355A1
(en)
|
2013-03-08 |
2014-09-12 |
Vaccinex, Inc. |
Anti-cxcl13 antibodies and associated epitope sequences
|
SI2968588T1
(sl)
|
2013-03-15 |
2019-05-31 |
AbbVie Deutschland GmbH & Co. KG |
Formulacije konjugatov protitelo proti-EGFR zdravilo
|
EP2970396B1
(de)
|
2013-03-15 |
2022-02-23 |
Biological Mimetics, Inc. |
Immunogene zusammensetzungen des menschlichen rhinovirus (hrv)
|
JP2016519070A
(ja)
|
2013-03-15 |
2016-06-30 |
アッヴィ・インコーポレイテッド |
抗体薬物複合体(adc)の精製
|
US9920377B2
(en)
|
2013-03-15 |
2018-03-20 |
Sutter West Bay Hospitals |
FALZ for use as a target for therapies to treat cancer
|
SG11201509982UA
(de)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
EP2818867A1
(de)
|
2013-06-27 |
2014-12-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An mindestens ein Nucleinsäuremolekül konjugierte Antikörper und deren Verwendung in Multiplex-Immunnachweis-Assays
|
US20160176943A1
(en)
|
2013-07-05 |
2016-06-23 |
Inserm (Insititut National De La Sante Et De La Recherche Medicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
US20160178610A1
(en)
|
2013-08-07 |
2016-06-23 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment Friedreich's ataxia
|
TW201722994A
(zh)
|
2013-08-13 |
2017-07-01 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
SG10201710013RA
(en)
|
2013-08-13 |
2018-01-30 |
Sanofi Sa |
Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
|
MX2016004605A
(es)
|
2013-10-24 |
2016-11-14 |
Astrazeneca Ab |
Formulaciones de anticuerpos estables acuosas.
|
CN105849125B
(zh)
|
2013-11-07 |
2020-05-15 |
国家医疗保健研究所 |
神经调节蛋白变构抗her3抗体
|
JP6870988B2
(ja)
|
2014-02-24 |
2021-05-19 |
セルジーン コーポレイション |
神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
CA2943242A1
(en)
|
2014-03-21 |
2015-09-24 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
CN106536556B
(zh)
|
2014-04-04 |
2020-02-07 |
生态学有限公司 |
结合lgr5的人源化抗体
|
FR3020063A1
(fr)
|
2014-04-16 |
2015-10-23 |
Gamamabs Pharma |
Anticorps humain anti-her4
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
US10308935B2
(en)
|
2014-06-23 |
2019-06-04 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
|
US20170165261A1
(en)
|
2014-07-01 |
2017-06-15 |
Brian Arthur Hemmings |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
WO2016046768A1
(en)
|
2014-09-24 |
2016-03-31 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
WO2016050822A2
(en)
|
2014-09-30 |
2016-04-07 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
US10625180B2
(en)
|
2014-10-31 |
2020-04-21 |
Arexis Ab |
Manufacturing method
|
SG11201703446RA
(en)
|
2014-10-31 |
2017-05-30 |
Abbvie Biotherapeutics Inc |
Anti-cs1 antibodies and antibody drug conjugates
|
ES2764299T3
(es)
|
2014-12-09 |
2020-06-02 |
Inst Nat Sante Rech Med |
Anticuerpos monoclonales humanos contra AXL
|
CA2970155A1
(en)
|
2014-12-09 |
2016-06-16 |
Abbvie Inc. |
Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
|
JP2018502839A
(ja)
|
2014-12-09 |
2018-02-01 |
アッヴィ・インコーポレイテッド |
Bcl−xL阻害性化合物およびこれを含む抗体薬物コンジュゲート
|
BR112017012377A2
(pt)
|
2014-12-09 |
2018-04-24 |
Abbvie Inc |
conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
|
EP3229838B1
(de)
|
2014-12-11 |
2020-09-09 |
Pierre Fabre Medicament |
Anti-c10orf54-antikörper und verwendungen davon
|
MX2017009038A
(es)
|
2015-01-08 |
2017-10-25 |
Biogen Ma Inc |
Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
|
WO2016139482A1
(en)
|
2015-03-03 |
2016-09-09 |
Kymab Limited |
Antibodies, uses & methods
|
EP3277717B1
(de)
|
2015-03-31 |
2020-11-18 |
Medimmune Limited |
Neuartige il33-form, mutierte formen von il33, antikörper, tests und verfahren zur verwendung davon
|
EP3091033A1
(de)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3-antikörper und verwendungen davon
|
WO2016188911A1
(en)
|
2015-05-22 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
|
CA2997673A1
(en)
|
2015-09-15 |
2017-03-23 |
Board Of Regents, The University Of Texas System |
T-cell receptor (tcr)-binding antibodies and uses thereof
|
CN108291257B
(zh)
|
2015-09-24 |
2023-12-29 |
阿布维特罗有限责任公司 |
亲和-寡核苷酸缀合物及其用途
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
JP2019500327A
(ja)
|
2015-11-30 |
2019-01-10 |
アッヴィ・インコーポレイテッド |
抗huLRRC15抗体薬物コンジュゲート及びその使用方法
|
WO2017095808A1
(en)
|
2015-11-30 |
2017-06-08 |
Abbvie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
US10472422B2
(en)
|
2016-01-08 |
2019-11-12 |
Abgenomics International Inc. |
Tetravalent anti-PSGL-1 antibodies and uses thereof
|
US10745487B2
(en)
|
2016-03-22 |
2020-08-18 |
Bionomics Limited |
Method of treating cancer by administering an anti-LGR5 monoclonal antibody
|
KR102640157B1
(ko)
|
2016-03-22 |
2024-02-27 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
인간화 항-클라우딘-1 항체 및 이의 용도
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
KR20230028574A
(ko)
|
2016-05-17 |
2023-02-28 |
애브비 바이오테라퓨틱스 인크. |
항-cMet 항체 약물 컨쥬게이트 및 그들의 이용 방법
|
WO2017214456A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
CN109563167A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
CN109562170B
(zh)
|
2016-06-08 |
2023-01-13 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
CA3027103A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
EP4104865A1
(de)
|
2016-06-08 |
2022-12-21 |
AbbVie Inc. |
Anti-egfr-antikörper-wirkstoff-konjugate
|
WO2017214335A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
AU2017277422A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-EGFR antibody drug conjugates
|
MX2018015280A
(es)
|
2016-06-08 |
2019-08-12 |
Abbvie Inc |
Conjugados de anticuerpo y farmaco anti-egfr.
|
EP3468599A2
(de)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98-antikörper und antikörperwirkstoffkonjugate
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
BR112019005748A2
(pt)
|
2016-09-24 |
2019-06-18 |
Abvitro Llc |
afinidade-conjugados de oligonucleotídeo e usos destes
|
WO2018077926A1
(en)
|
2016-10-25 |
2018-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Monoclonal antibodies binding to the cd160 transmembrane isoform
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
WO2018091621A1
(en)
|
2016-11-17 |
2018-05-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for increasing endogenous protein level
|
US11471538B2
(en)
|
2017-02-10 |
2022-10-18 |
INSERM (Institut National de la Santéet de la Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
TW201836647A
(zh)
|
2017-04-06 |
2018-10-16 |
美商艾伯維有限公司 |
抗-prlr抗體藥物軛合物(adc)及其用途
|
KR20200004324A
(ko)
|
2017-05-05 |
2020-01-13 |
백시넥스 인코포레이티드 |
인간 항-세마포린 4d 항체
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
WO2019102435A1
(en)
|
2017-11-27 |
2019-05-31 |
Euro-Celtique S.A. |
Humanized antibodies targeting human tissue factor
|
EP3498293A1
(de)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
|
US20210070819A1
(en)
|
2018-03-16 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
|
WO2019175384A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
EP3765064A1
(de)
|
2018-03-16 |
2021-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pcsk2-abgeleitete antigene peptide und verwendungen davon zur diagnose und behandlung von diabetes typ 1
|
WO2019180150A1
(en)
|
2018-03-22 |
2019-09-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
|
JP2021521273A
(ja)
|
2018-04-12 |
2021-08-26 |
メディアファーマ エス.アール.エル. |
Lgals3bp抗体−薬剤結合体及びがん治療のためのその使用
|
AU2019277029C1
(en)
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
WO2020058372A1
(en)
|
2018-09-19 |
2020-03-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
EP3877413A1
(de)
|
2018-11-06 |
2021-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von akuter myeloischer leukämie durch vernichtung von leukämischen stammzellen
|
JP2022516408A
(ja)
|
2018-12-14 |
2022-02-28 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
単離されたMHC由来ヒトペプチドおよびCD8+CD45RClowTregの抑制機能を刺激し、かつ活性化するためのその使用
|
EP3898699A1
(de)
|
2018-12-19 |
2021-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur behandlung von krebs durch immunmodulation unter verwendung von antikörpern gegen cathespin-d
|
WO2020163225A1
(en)
|
2019-02-05 |
2020-08-13 |
Seattle Genetics, Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
SG11202108560RA
(en)
|
2019-02-13 |
2021-09-29 |
Brigham & Womens Hospital Inc |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
MA55529A
(fr)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
|
JP2022538733A
(ja)
|
2019-05-20 |
2022-09-06 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
新規抗cd25抗体
|
JP2022532928A
(ja)
|
2019-05-24 |
2022-07-20 |
サノフイ |
全身性硬化症を治療するための方法
|
JPWO2021060439A1
(de)
|
2019-09-26 |
2021-04-01 |
|
|
EP4037710A1
(de)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und pharmazeutische zusammensetzung zur behandlung von eierstockkrebs, brustkrebs oder bauchspeicheldrüsenkrebs
|
CN115151564A
(zh)
|
2019-10-04 |
2022-10-04 |
思进股份有限公司 |
抗pd-l1抗体和抗体-药物缀合物
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
WO2021116119A1
(en)
|
2019-12-09 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
CN115315446A
(zh)
|
2020-03-06 |
2022-11-08 |
Go医疗股份有限公司 |
抗糖-cd44抗体及其用途
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
EP4149558A1
(de)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
|
CA3182333A1
(en)
|
2020-05-20 |
2021-11-25 |
Institut Curie |
Single domain antibodies and their use in cancer therapies
|
JP2023528017A
(ja)
|
2020-05-26 |
2023-07-03 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
重症急性呼吸器症候群コロナウイルス2(sars-cov-2)ポリペプチドおよびワクチン目的でのその使用
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
AU2021320739A1
(en)
|
2020-08-04 |
2023-02-23 |
Seagen Inc. |
Anti-CD228 antibodies and antibody-drug conjugates
|
EP4229081A1
(de)
|
2020-10-15 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Für sars-cov-2-rezeptor-bindungsdomäne spezifischer antikörper und therapeutische verfahren
|
WO2022079270A1
(en)
|
2020-10-16 |
2022-04-21 |
Université D'aix-Marseille |
Anti-gpc4 single domain antibodies
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
EP4244253A1
(de)
|
2020-11-12 |
2023-09-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
An die rezeptorbindungsdomäne des sars-cov-2-spikeproteins konjugierte oder fusionierte antikörper und verwendungen davon für impfstoffzwecke
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
MX2023007610A
(es)
|
2020-12-23 |
2023-07-12 |
Inserm Institut National De La Sante Et De La Rech Medicale |
Vacuna contra clamidia basada en el direccionamiento del antigeno momp vs4 a las celulas presentadoras de antigeno.
|
US20240115721A1
(en)
|
2021-01-13 |
2024-04-11 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
KR20230146521A
(ko)
|
2021-01-13 |
2023-10-19 |
메모리얼 슬로안 케터링 캔서 센터 |
항체-피롤로벤조디아제핀 유도체 접합체
|
IL304031A
(en)
|
2021-01-14 |
2023-08-01 |
Inst Curie |
Variants of single-domain HER2 antibodies and their chimeric antigenic receptors
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
JP2024504195A
(ja)
|
2021-01-29 |
2024-01-30 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
クラミジア・トラコマチス抗原性ポリペプチドおよびワクチン目的のためのその使用
|
CN117321076A
(zh)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
中和SARS-CoV-2的单结构域抗体
|
EP4301782A1
(de)
|
2021-03-05 |
2024-01-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44-antikörper und deren verwendungen
|
WO2022200303A1
(en)
|
2021-03-23 |
2022-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of t cell-lymphomas
|
EP4320153A1
(de)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur behandlung von anaplastischem grosszelligem lymphom
|
WO2022223488A1
(en)
|
2021-04-19 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
|
WO2022263451A1
(en)
|
2021-06-15 |
2022-12-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Peptides derived from the spike protein of sars-cov-2 and uses thereof for diagnosis and vaccine purposes
|
WO2023014863A1
(en)
|
2021-08-05 |
2023-02-09 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
TW202325733A
(zh)
|
2021-09-03 |
2023-07-01 |
美商Go治療公司 |
抗醣化-lamp1抗體及其用途
|
CA3230934A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
WO2023088968A1
(en)
|
2021-11-17 |
2023-05-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Universal sarbecovirus vaccines
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024074571A1
(en)
|
2022-10-05 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Dc-targeting vaccine against nipah virus infection
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|